HIVAC-1e
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID), Bristol-Myers Squibb
Conditions
HIV Infections
Phase 1
Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)
CompletedNCT00000630
End: 1992-12-31Target: 35Updated: 2021-10-27
A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)
CompletedNCT00000631
End: 1992-12-31Target: 13Updated: 2021-11-02
A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus
CompletedNCT00000683
End: 1993-06-30Target: 54Updated: 2021-11-02
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals
CompletedNCT00001026
End: 1994-12-31Target: 56Updated: 2021-11-04
A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers
CompletedNCT00002261
Updated: 2007-09-26
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines
CompletedNCT00000746
End: 1994-07-31Target: 56Updated: 2021-11-04